Q2 2023 13F Holders as of 6/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
26.6M
-
Shares change
-
-1.28M
-
Total reported value, excl. options
-
$93.8M
-
Value change
-
-$4.38M
-
Put/Call ratio
-
0.14
-
Number of buys
-
15
-
Number of sells
-
-42
-
Price
-
$3.53
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2023
86 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q2 2023.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 26.6M shares
of 49.6M outstanding shares and own 53.55% of the company stock.
Largest 10 shareholders include Camber Capital Management LP (4.24M shares), VANGUARD GROUP INC (3.76M shares), MILLENNIUM MANAGEMENT LLC (2.81M shares), ACADIAN ASSET MANAGEMENT LLC (1.87M shares), Athyrium Capital Management, LP (1.79M shares), RENAISSANCE TECHNOLOGIES LLC (1.76M shares), Eversept Partners, LP (1.66M shares), BlackRock Inc. (1.52M shares), Hillsdale Investment Management Inc. (803K shares), and GLOBEFLEX CAPITAL L P (562K shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.